TABLETS & CAPSULES

www.tabletscapsules.com

October 2020

Volume 18 Number 7

In this issue of Tablets & Capsules, we discuss how COVID-19 is impacting FDA inspections, how to ensure excipient quality using QbD, and how a submission stage gate system can improve drug product development results. Elsewhere in the issue, we examine natural alternative excipients for solid dose products; the differences between validation, verification, and monitoring of blister pack inspection systems; and changes to dietary supplement labeling requirements. Finally, our Eye on Excipients column explores orodispersible minitablets, and on the Back Page, we learn how to evaluate and minimize powder transfer risks when working with a CMO.

QUALITY, VALIDATION, & REGULATORY COMPLIANCE

ALSO IN THIS ISSUE

DEPARTMENTS

Tablets & Capsules (ISSN 1549-9928 print; ISSN 1938-9159 online) is published by CSC Publishing, Inc, 1155 Northland Drive, Saint Paul, MN 55120.